Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review
BackgroundPrimary squamous cell carcinoma of the thyroid (PSCCT) is a rare malignant tumor. The incidence rate of PSCCT is less than 1%. However, the diagnosis and treatment of PSCCT are limited. Surgical resection is considered to be one of the few effective intervention methods. In this article, w...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.976415/full |
| _version_ | 1797869199005057024 |
|---|---|
| author | Zichang Liu Maosheng Yu Feng Zhao Chenfang Zhu |
| author_facet | Zichang Liu Maosheng Yu Feng Zhao Chenfang Zhu |
| author_sort | Zichang Liu |
| collection | DOAJ |
| description | BackgroundPrimary squamous cell carcinoma of the thyroid (PSCCT) is a rare malignant tumor. The incidence rate of PSCCT is less than 1%. However, the diagnosis and treatment of PSCCT are limited. Surgical resection is considered to be one of the few effective intervention methods. In this article, we reported a case of taking tyrosine kinase inhibitors (TKIs) combined with immune checkpoint inhibitors (ICIs) for PSCCT.Case summaryAn 80-year-old male was admitted to our hospital with dyspnea, cough, wheezing, and hoarseness for a giant thyroid mass. He underwent bronchoscopy and tracheal stent implantation to alleviate the respiratory obstruction. Then he accepted right partial thyroid and right lymph node biopsy. Postoperative pathology revealed squamous cell carcinoma. Subsequently, he underwent an endoscopy to exclude upper gastrointestinal squamous cell carcinoma. Finally, he was diagnosed with PSCCT. The patient was tentatively treated with a combination of Anlotinib and Sintilimab. After two courses, the tumor volume significantly reduced in MRI images and shrank further after five courses of combined treatment. Unfortunately, the patient died of fulminant liver failure and autoimmune liver disease after 5-month-treatment.ConclusionTKIs combined with ICIs may be an effective and novel way for PSCCT treatment, but immune-related complications, especially liver damage, should be cared. |
| first_indexed | 2024-04-10T00:07:48Z |
| format | Article |
| id | doaj.art-6df1901100584ab696ecba73edc523bf |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T00:07:48Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-6df1901100584ab696ecba73edc523bf2023-03-16T17:02:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.976415976415Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature reviewZichang LiuMaosheng YuFeng ZhaoChenfang ZhuBackgroundPrimary squamous cell carcinoma of the thyroid (PSCCT) is a rare malignant tumor. The incidence rate of PSCCT is less than 1%. However, the diagnosis and treatment of PSCCT are limited. Surgical resection is considered to be one of the few effective intervention methods. In this article, we reported a case of taking tyrosine kinase inhibitors (TKIs) combined with immune checkpoint inhibitors (ICIs) for PSCCT.Case summaryAn 80-year-old male was admitted to our hospital with dyspnea, cough, wheezing, and hoarseness for a giant thyroid mass. He underwent bronchoscopy and tracheal stent implantation to alleviate the respiratory obstruction. Then he accepted right partial thyroid and right lymph node biopsy. Postoperative pathology revealed squamous cell carcinoma. Subsequently, he underwent an endoscopy to exclude upper gastrointestinal squamous cell carcinoma. Finally, he was diagnosed with PSCCT. The patient was tentatively treated with a combination of Anlotinib and Sintilimab. After two courses, the tumor volume significantly reduced in MRI images and shrank further after five courses of combined treatment. Unfortunately, the patient died of fulminant liver failure and autoimmune liver disease after 5-month-treatment.ConclusionTKIs combined with ICIs may be an effective and novel way for PSCCT treatment, but immune-related complications, especially liver damage, should be cared.https://www.frontiersin.org/articles/10.3389/fonc.2023.976415/fullprimary squamous cell carcinoma of the thyroidtyrosine kinase inhibitorsimmune checkpoint inhibitorsAnlotinibSintilimabimmune-related adverse reactions |
| spellingShingle | Zichang Liu Maosheng Yu Feng Zhao Chenfang Zhu Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review Frontiers in Oncology primary squamous cell carcinoma of the thyroid tyrosine kinase inhibitors immune checkpoint inhibitors Anlotinib Sintilimab immune-related adverse reactions |
| title | Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review |
| title_full | Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review |
| title_fullStr | Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review |
| title_full_unstemmed | Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review |
| title_short | Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review |
| title_sort | anlotinib combined with sintilimab is win win cooperation for primary squamous cell carcinoma of the thyroid a case report and literature review |
| topic | primary squamous cell carcinoma of the thyroid tyrosine kinase inhibitors immune checkpoint inhibitors Anlotinib Sintilimab immune-related adverse reactions |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.976415/full |
| work_keys_str_mv | AT zichangliu anlotinibcombinedwithsintilimabiswinwincooperationforprimarysquamouscellcarcinomaofthethyroidacasereportandliteraturereview AT maoshengyu anlotinibcombinedwithsintilimabiswinwincooperationforprimarysquamouscellcarcinomaofthethyroidacasereportandliteraturereview AT fengzhao anlotinibcombinedwithsintilimabiswinwincooperationforprimarysquamouscellcarcinomaofthethyroidacasereportandliteraturereview AT chenfangzhu anlotinibcombinedwithsintilimabiswinwincooperationforprimarysquamouscellcarcinomaofthethyroidacasereportandliteraturereview |